Celecoxib — Drug Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

6 Recruiting

4 Completed trials

13 Sponsors

14 Countries

Phase III

Phase II

Phase IV

Phase III: 4 Phase II: 2 Phase IV: 4 Phase I (Other): 1 Other: 1

Oversight events:

2 serious breaches 2 temporary halts 1 corrective measure across 2 trials

View oversight register →

Indications tested

Axial spondyloarthritis 1 Pancreatitis chronic 1 Myeloproliferative neoplasm 1 Myelofibrosis 1

Sponsors using this IMP

AbbVie Deutschland GmbH & Co. KG 1 Amsterdam UMC Stichting 1 Apurano Pharmaceuticals GmbH 1 Cannaxan GmbH 1 Centre Hospitalier Universitaire Amiens Picardie 1 Codadose Inc. 1 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 1 Hvidovre Hospital 1 Medical University Of Vienna 1 Odense University Hospital 1 Semmelweis University 1 St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr 1

All trials

12 total

Comparison of the preventive painkiller effect of etoricoxib and celecoxib after M3M surgery: A randomized, double-masked clinical trial Pending

2025-520695-26-00 Phase IV 1 country Semmelweis University
COPE-CP: The effect of Celecoxib on pain, quality of life, use of opioids, and inflammation in patients suffering from chronic pancreatitis Pending

2025-522956-25-00 Phase III 1 country Odense University Hospital
Evaluation of postoperative recovery when combining intravenous lidocaine with ropivacaine infiltration in laparoscopic colorectal oncologic… Recruiting

2025-523207-29-00 Phase IV 1 country Centre Hospitalier Universitaire Amiens Picardie
Direct comparison between NSAIDs and biosimilar TNFa blockers in patients with axial spondyloarthritis Recruiting

2024-513213-13-00 Phase IV 1 country St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr
Precision psychiatry: Anti-inflammatory medication in Immuno-metabolic depression Recruiting

2024-513907-15-01 Phase III 1 country Amsterdam UMC Stichting
INSTA-MD: INflammation-based Stratification for immune-Targeted Augmentation in Major Depressive disorder Recruiting

2022-501692-35-00 Phase III 1 country University Of Antwerp
Neoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer - the NICHE trial Recruiting

2024-513314-35-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
MEMMAT - Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial Recruiting

2024-515626-92-00 Phase II 7 countries Medical University Of Vienna
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants Wit… Ended

2023-507274-40-00 Phase I (Other) 6 countries AbbVie Deutschland GmbH & Co. KG
Efficacy and Tolerability of AP707 in Patients with Chronic Back Pain Ended

2022-502151-54-00 Phase III 2 countries Apurano Pharmaceuticals GmbH; Cannaxan GmbH
Single Dose Crossover Comparative Bioavailability and Food Effect Study of Celecoxib 10 mg/1 mL Oral Suspension versus Celebrex®️ (celecoxib… Ended

2023-504052-99-00 1 country Codadose Inc.
Clinical trial on Spinal Anaesthesia vs. General Anaesthesia (SAGA) on recovery after hip and knee replacements Ended

2022-501221-21-00 Phase IV 1 country Hvidovre Hospital

Showing 1–12 of 12 trials

← All drugs A–Z